JP2022541234A - 第２世代セネカバレーウイルス腫瘍溶解性療法：その構成と方法 - Google Patents

第２世代セネカバレーウイルス腫瘍溶解性療法：その構成と方法 Download PDF

Info

Publication number
JP2022541234A
JP2022541234A JP2022502812A JP2022502812A JP2022541234A JP 2022541234 A JP2022541234 A JP 2022541234A JP 2022502812 A JP2022502812 A JP 2022502812A JP 2022502812 A JP2022502812 A JP 2022502812A JP 2022541234 A JP2022541234 A JP 2022541234A
Authority
JP
Japan
Prior art keywords
cancer
ifn
svv
inhibitor
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022502812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541234A5 (https=
Inventor
アール． ラカニエッロ、ヴィンセント
ビー． ローゼンフェルド、エイミー
エル． ハレンベック、ポール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of JP2022541234A publication Critical patent/JP2022541234A/ja
Publication of JP2022541234A5 publication Critical patent/JP2022541234A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022502812A 2019-07-19 2020-07-20 第２世代セネカバレーウイルス腫瘍溶解性療法：その構成と方法 Pending JP2022541234A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962876191P 2019-07-19 2019-07-19
US62/876,191 2019-07-19
PCT/US2020/042795 WO2021016194A1 (en) 2019-07-19 2020-07-20 Second generation seneca valley virus oncolytic therapy: compositions and methods thereof

Publications (2)

Publication Number Publication Date
JP2022541234A true JP2022541234A (ja) 2022-09-22
JP2022541234A5 JP2022541234A5 (https=) 2023-07-26

Family

ID=74193871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502812A Pending JP2022541234A (ja) 2019-07-19 2020-07-20 第２世代セネカバレーウイルス腫瘍溶解性療法：その構成と方法

Country Status (10)

Country Link
US (1) US12502414B2 (https=)
EP (1) EP3999087A4 (https=)
JP (1) JP2022541234A (https=)
KR (1) KR20220035931A (https=)
CN (1) CN115038456A (https=)
AU (1) AU2020315800A1 (https=)
BR (1) BR112022000928A2 (https=)
CA (1) CA3147640A1 (https=)
IL (1) IL289912A (https=)
WO (1) WO2021016194A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017096201A1 (en) 2015-12-02 2017-06-08 Memorial Sloan-Kettering Cancer Center Seneca valley virus (svv) cellular receptor targeted oncotherapy
BR112022000928A2 (pt) 2019-07-19 2022-03-08 Seneca Therapeutics Inc Terapia oncolítica do vírus seneca valley de segunda geração: composições e métodos da mesma
CN116059260A (zh) * 2023-03-07 2023-05-05 华南农业大学 Sva病毒在制备肿瘤防治药物中的应用及抗肿瘤组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120100109A1 (en) * 2010-10-26 2012-04-26 Xiaoliu Zhang Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors
WO2017096201A1 (en) * 2015-12-02 2017-06-08 Memorial Sloan-Kettering Cancer Center Seneca valley virus (svv) cellular receptor targeted oncotherapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US20030129215A1 (en) 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
MXPA06003318A (es) 2003-09-26 2006-06-08 Novartis Ag Composiciones a base de virus de seneca valley y metodos para tratar la enfermedad.
US7638318B2 (en) 2003-09-26 2009-12-29 Norvartis Ag Seneca Valley virus based compositions and methods for treating disease
ITRM20060337A1 (it) 2006-06-27 2007-12-28 Biosoot Srl Gene tem8 (tumor endotelial marker 8) e sue forme di espressione ed usi diagnostici e terapeutici
WO2008112891A2 (en) 2007-03-13 2008-09-18 Neotropix, Inc. Monoclonal antibody that recognizes a seneca valley virus (svv) cellular receptor and uses thereof
US20100183633A1 (en) 2008-12-04 2010-07-22 University Of Massachusetts Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition
EP2637692A4 (en) 2010-11-12 2014-09-10 Scott & White Healthcare ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8
SG192673A1 (en) 2011-02-10 2013-09-30 Roche Glycart Ag Mutant interleukin-2 polypeptides
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
GB201217892D0 (en) 2012-10-05 2012-11-21 Virttu Biolog Ltd Treatment of cancer
WO2014089124A1 (en) 2012-12-03 2014-06-12 Cenexys, Inc. Immunogenic compositions for inducing an immune response for elimination of senescent cells
RU2696312C2 (ru) 2014-07-16 2019-08-01 Трансген Са Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
MY203926A (en) 2016-02-24 2024-07-24 Childrens Hospital Of Eastern Ontario Res Institute Inc Smc combination therapy for the treatment of cancer
WO2018049248A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus equipped with bispecific engager molecules
KR102056066B1 (ko) 2016-12-09 2019-12-17 진메디신 주식회사 세포외 기질 분해 인자를 발현하는 재조합 아데노바이러스를 포함하는 항암용 조성물
CN111201035A (zh) 2017-06-19 2020-05-26 梅迪塞纳医疗股份有限公司 Il-2超激动剂、激动剂及其融合体的用途和方法
CN109022374B (zh) 2018-08-16 2021-05-14 华中农业大学 一种塞内卡谷病毒重组质粒、重组病毒及构建方法
MX2021001883A (es) 2018-08-16 2021-07-15 Musc Found For Res Dev Virus recombinantes del mixoma y usos de los mismos.
US20220000921A1 (en) 2018-11-20 2022-01-06 Innovative Cellular Therapeutics Holdings, Ltd. Modified Cell Expressing Therapeutic Agent and Uses thereof
JP2022516318A (ja) 2019-01-04 2022-02-25 オンコラス， インコーポレイテッド カプセル化ポリヌクレオチド及び使用方法
US20220119478A1 (en) 2019-01-15 2022-04-21 Caerus Therapeutics, Corp. Advanced chimeric antigen receptor vectors for targeting solid tumors
WO2020210711A1 (en) 2019-04-11 2020-10-15 Seneca Therapeutics, Inc. Compositions and methods of using seneca valley virus (svv) for treating cancer
BR112022000928A2 (pt) 2019-07-19 2022-03-08 Seneca Therapeutics Inc Terapia oncolítica do vírus seneca valley de segunda geração: composições e métodos da mesma
CN111154806A (zh) 2020-01-08 2020-05-15 深圳普菲科生命科技有限公司 一种嵌合外源超级细胞因子的溶瘤病毒载体系统及其在药物中的应用
CA3207860A1 (en) 2021-01-11 2022-07-14 Seneca Therapeutics, Inc. Seneca valley virus combination therapy to treat a cancer refractory to a checkpoint inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120100109A1 (en) * 2010-10-26 2012-04-26 Xiaoliu Zhang Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors
WO2017096201A1 (en) * 2015-12-02 2017-06-08 Memorial Sloan-Kettering Cancer Center Seneca valley virus (svv) cellular receptor targeted oncotherapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NEURO-ONCOLOGY, vol. 13, no. 1, JPN7024002597, 2011, pages 14 - 27, ISSN: 0005552301 *
PNAS, vol. 107, no. 4, JPN6024023902, 2010, pages 1576 - 1581, ISSN: 0005552303 *
THE JOURNAL OF CLINICAL INVESTIGATION, vol. 127, no. 8, JPN6024023901, 2017, pages 2957 - 2967, ISSN: 0005552302 *

Also Published As

Publication number Publication date
BR112022000928A2 (pt) 2022-03-08
CA3147640A1 (en) 2021-01-28
US12502414B2 (en) 2025-12-23
KR20220035931A (ko) 2022-03-22
EP3999087A1 (en) 2022-05-25
EP3999087A4 (en) 2023-08-23
IL289912A (en) 2022-03-01
AU2020315800A1 (en) 2022-03-03
WO2021016194A1 (en) 2021-01-28
US20220249584A1 (en) 2022-08-11
CN115038456A (zh) 2022-09-09

Similar Documents

Publication Publication Date Title
Galluzzi et al. Immunological effects of conventional chemotherapy and targeted anticancer agents
US10821142B2 (en) Cancer treatment and diagnosis
K. Kontos et al. Apoptosis-related BCL2-family members: Key players in chemotherapy
US20200255527A1 (en) Methods of treating cancer using lsd1 inhibitors in combination with immunotherapy
TW201938796A (zh) 使用atr抑制劑治療癌症之方法
US20250134941A1 (en) Hsv-1 oncolytic virus therapies that specifically kill alt dependent cancers
TWI895295B (zh) 偵測編碼新生抗原之融合基因之方法
JP2022541234A (ja) 第２世代セネカバレーウイルス腫瘍溶解性療法：その構成と方法
US20240342211A1 (en) Short-term activated dc1s and methods for their production and use
Chen et al. STING-dependent interferon-λ1 induction in HT29 cells, a human colorectal cancer cell line, after gamma-radiation
JP2022527412A (ja) がんの治療にセネカバレーウイルス（ｓｖｖ）を使用する組成物および方法
CN117045800A (zh) mTOR抑制剂增强靶向蛋白降解药物功效的应用
JP2024502615A (ja) チェックポイント阻害剤抵抗性のがんを治療するためのセネカバレーウイルス併用療法
CN115998872A (zh) 一种含有抑制核酸内切酶功能的药物及其抗肿瘤的用途
WO2017142818A1 (en) Improved interferon therapy
JP2024503703A (ja) 武装型セネカバレーウイルス腫瘍溶解療法組成物およびその方法
US20230365673A1 (en) Means for reducing radio- and chemotherapy resistance and adverse effects
US12173039B1 (en) TPL2 inhibiting agents, uses thereof, and detection of TPL2
Sinkovics Adult human sarcomas. II. Medical oncology
El-Sayes IMPROVING OUTCOMES FOR CANCER IMMUNOTHERAPY
Doherty Interferon-beta Regulates Cancer Stem Cell Plasticity to Promote Positive Clinical Outcome in Triple-negative Breast Cancer
WO2024206658A2 (en) Compositions and methods for treating melanoma
Huang Characterization of the immunosuppressive tumour microenvironment in a mouse model of clear cell renal cell carcinoma
Tsai Identification and Characterization of Regorafenib and NU7441 as Targeted Immunotherapies for Melanoma
We Emerging Treatments for Malignant

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230718

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230718

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250318